DonaldMO'RourkeMD
Neurosurgery • Philadelphia, PABrain & Spinal Tumor
Associate Professor, Neurosurgery, University of Pennsylvania School of Medicine
Dr. O'Rourke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Fl 3
Philadelphia, PA 19104Phone+1 215-662-3487Fax+1 215-349-5534
Education & Training
University of Pennsylvania Health SystemResidency, Neurological Surgery, 1988 - 1994
Perelman School of Medicine at the University of PennsylvaniaClass of 1987
Certifications & Licensure
PA State Medical License 1988 - 2024- American Board of Neurological Surgery Neurological Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma Start of enrollment: 2014 Nov 18
- Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies Start of enrollment: 2016 May 23
- CART-EGFRvIII + Pembrolizumab in GBM Start of enrollment: 2019 Mar 11
Publications & Presentations
PubMed
- 113 citationsEpidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.Zev A. Binder, Amy Haseley Thorne, Spyridon Bakas, E. Paul Wileyto, Michel Bilello
Cancer Cell. 2018-07-09 - 174 citationsVascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α.Qirui Wang, Zhenqiang He, Menggui Huang, Tianrun Liu, Yanling Wang
Nature Communications. 2018-02-08 - 1134 citationsA single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.Donald M. O'Rourke, MacLean Nasrallah, Arati Desai, J. Joseph Melenhorst, Keith Mansfield
Science Translational Medicine. 2017-07-19
Press Mentions
New Penn Medicine Center Brings Immunotherapy Research to Brain Tumor TreatmentOctober 30th, 2018
Dual-Target Cell Therapy Shrinks Brain Tumors: Penn MedMarch 19th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
